Abstract
Enhanced macropinocytosis has been found in K-Ras mutant pancreatic cancer cells, through which albumin can massively enter into the K-Ras-driven cancer cells, suggesting its role in serving as a macropinocytosis-intensifying drug delivery carrier. In the present study, a novel recombinant protein Fv-LDP-D3 and its reconstituted analogue Fv-LDP-D3-AE were designed and prepared. Fv is the fragment of an anti-EGFR antibody, D3 is the domain III of human serum albumin (HSA), LDP is the apoprotein of the antitumor antibiotic lidamycin (LDM), and AE is an extremely cytotoxic enediyne chromophore derived from LDM. As shown, the recombinant protein Fv-LDP-D3 presented intensive and selective binding capacity to pancreatic cancer cells and inhibited cell proliferation by blocking EGFR signaling. Moreover, Fv-LDP-D3 showed prominent tumor imaging in pancreatic carcinoma xenograft. The reconstituted, enediyne-integrated analogue Fv-LDP-D3-AE displayed highly potent cytotoxicity to pancreatic cancer cells through apoptosis induction and G2/M arrest. Fv-LDP-D3 and Fv-LDP-D3-AE markedly inhibited the tumor growth of the pancreatic carcinoma AsPC-1 xenograft. Study results indicated that the novel recombinant protein displays both EGFR-targe...Continue Reading
References
Jun 24, 2004·Pancreas·Shigeto UedaHidetaka Mochizuki
Nov 27, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ikuhiko NakaseShiroh Futaki
Jun 28, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Felix Kratz
Apr 8, 2009·Proceedings of the American Thoracic Society·Gregory J RielyWilliam Pao
Aug 31, 2010·Protein Engineering, Design & Selection : PEDS·Vania E KenanovaAnna M Wu
Dec 30, 2011·Anti-cancer Drugs·Weijin ShengYongsu Zhen
Jan 5, 2012·Nature Communications·Jan Terje AndersenInger Sandlie
Jun 23, 2012·Nature·Sandra MisaleAlberto Bardelli
May 15, 2013·Nature·Cosimo CommissoDafna Bar-Sagi
Jul 3, 2013·The Journal of Biological Chemistry·Jan Terje AndersenInger Sandlie
Feb 1, 2014·Cell Death & Disease·J TrebingH Wajant
Mar 4, 2014·Cellular Signalling·Ellen J TisdaleCristina R Artalejo
May 24, 2014·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yin XiangbaoFu Huaqun
Apr 13, 2015·EMBO Molecular Medicine·Hongsik LeeJunseo Oh
Jun 4, 2015·Scientific Reports·Ikuhiko NakaseTetsuhiko Yoshida
Sep 1, 2015·Oncotarget·Jian XuYong-Su Zhen
Nov 3, 2015·Biomaterials·Yuan LuXinling Ren
Mar 18, 2016·Journal of Cell Science·G Aaron HobbsKent L Rossman
Mar 25, 2016·Clinical and Translational Gastroenterology·Barbara BournetLouis Buscail
Jun 3, 2016·Molecular Pharmaceutics·Hong LiRobert J Lee
Aug 10, 2016·Cancer Letters·Mira WoitokKatharina Kolberg
Aug 16, 2016·Oncotarget·Yue DuYong-Su Zhen
Sep 28, 2016·Frontiers in Physiology·Kevin D HaBin Liu
Jan 18, 2017·Cancer Letters·Janaiah KotaMurray Korc
Feb 22, 2017·Clinical Colorectal Cancer·Federica TosiSalvatore Siena
Apr 11, 2017·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Jian XuYong-Su Zhen
Apr 27, 2017·International Journal of Molecular Sciences·Jaseela ChiramelMairéad G McNamara
May 11, 2017·Nature Communications·Jia-Lin HuangXiao-Ling Gao
Dec 19, 2017·Drug Delivery·Jian XuYong-Su Zhen
Citations
Dec 8, 2020·Scandinavian Journal of Gastroenterology·Carl AndreassonRoland Andersson
Dec 5, 2020·Expert Opinion on Drug Discovery·Mahendra P Deonarain, Gokhan Yahioglu
May 1, 2021·Antibody Therapeutics·Mahendra P Deonarain, Quinn Xue
Jul 21, 2021·International Journal of Biological Macromolecules·Hong-Yu TaoYong-Su Zhen
Jul 11, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Imke Rudnik-Jansen, Kenneth A Howard
Mar 27, 2019·Bioconjugate Chemistry·Qing LiM Jack Borrok